Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.91 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.91 |
| ▸ | GLA | P06280 | 3/20 | 0.91 |
| ▸ | GAA | P10253 | 3/20 | 0.91 |
| ▸ | HPGD | P15428 | 3/20 | 0.91 |
| ▸ | MEN1 | O00255 | 3/20 | 0.86 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | GFER | P55789 | 1/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.69 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.69 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.69 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.69 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.65 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29103864 | 0.95 | KDM4E (0.83) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL29642733 | 0.93 | KDM4E (1.00) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12561695 | 0.93 | KDM4E (0.80) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL16497610 | 0.93 | MAPK14 (0.81) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12561579 | 0.91 | KDM4E (0.76) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12311111 | 0.90 | KDM4E (0.75) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL28500397 | 0.89 | KDM4E (0.74) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL5607119 | 0.88 | KDM4E (0.72) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL28904610 | 0.88 | MAPK13 (0.87) | KDM4EKMT2AALDH1A1GLAGAA | |
| SCHEMBL12561714 | 0.88 | KDM4E (0.72) | KDM4EKMT2AALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165489-A1 | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-27 | — | — | US | claimed |
| WO-2011139637-A1 | SMALL-MOLECULE MODULATORS OF HIV-1 CAPSID STABILITY AND METHODS THEREOF | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2011-11-10 | — | — | WO | claimed |
| US-20070259875-A1 | Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof | REDPOINT BIO CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-12590125-B2 | Peptide inhibitors for the inhibition of HIV capsid | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2026-03-31 | — | — | US | disclosed |
| CN-114302735-B | Peptide inhibitors for inhibiting HIV capsid | 密苏里大学管理者 | 2025-03-18 | — | — | CN | disclosed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| EP-4276106-A2 | METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE USING CONSERVED ELEMENT CONSTRUCTS | The United States of America as represented by the Secretary of the Department of Health and Human Services (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230340029-A1 | METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE USING CONSERVED ELEMENT CONSTRUCTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-10-26 | — | — | US | disclosed |
| EP-3294755-B1 | METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE USING CONSERVED ELEMENT CONSTRUCTS | THE US SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220306690-A1 | PEPTIDE INHIBITORS FOR THE INHIBITION OF HIV CAPSID | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2022-09-29 | — | — | US | disclosed |
| CN-111635361-B | Fluorescent compound and preparation method and application thereof | 五邑大学 | 2022-08-02 | — | — | CN | disclosed |
| EP-2015638-A2 | TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF | Redpoint Bio Corporation (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20070259875-A1 | Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof | REDPOINT BIO CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259875-A1 | Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof | REDPOINT BIO CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259875-A1 | Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof | REDPOINT BIO CORPORATION | 2007-11-08 | — | — | US | disclosed |
| WO-2007127479-A2 | TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127479-A2 | TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165489-A1 | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof | ZC3HAV1, MAVS, HAVCR2 | KDM4E 1542/4885KMT2A 3224/4885ALDH1A1 3672/4885 |
| US-20070259875-A1 | Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof | TAS1R3, TAS2R1, TAS1R1 | KDM4E 3422/4885KMT2A 3144/4885ALDH1A1 407/4885 |
| US-12590125-B2 | Peptide inhibitors for the inhibition of HIV capsid | VIP, QPCT, TPX2 | KDM4E 1920/4885KMT2A 1300/4885ALDH1A1 4844/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | KDM4E 418/4885KMT2A 100/4885ALDH1A1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.